Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Cervical Cancer Vaccine Coadministered With Combined Diphtheria-Tetanus-Acellular Pertussis-inactivated Poliovirus Vaccine to Girls and Young Women

Journal of Adolescent Health

Volumn 46, Issue 2, 2010, Pages 142-151

  Garcia Sicilia, José ^a   Schwarz, Tino F ^b   Carmona, Alfonso ^c   Peters, Klaus ^d   Malkin, Jean Elie ^e   Tran, Phu M ^f   Behre, Ulrich ^g   Iturbe, Enrique B ^h   Catteau, Gregory ⁱ   Thomas, Florence ⁱ   Dobbelaere, Kurt ⁱ   Descamps, Dominique ⁱ   Dubin, Gary ^j  

^a HOSPITAL INFANTIL LA PAZ   (Spain)

^b Stiftung Juliusspital   (Germany)

^c Instituto Hispalense de Pediatria   (Spain)

^d Praxis   (Germany)

^e INSTITUT PASTEUR   (France)

^f Cabinet Medical   (France)

^g Medical Practice Kehl   (Germany)

^h Universidad Pública de Navarra   (Spain)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Adolescent; Adverse effects; Diphtheria tetanus acellular pertussis inactivated poliovirus vaccine; Female; Immunology; Papillomavirus vaccines; Randomized controlled trial

Indexed keywords

CANCER VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; PERTACTIN; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NONHUMAN; OPEN STUDY; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TETANUS; URTICARIA; UTERINE CERVIX CANCER; VACCINATION;

EID: 74549177126     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2009.11.205     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Cutts F.T., Franceschi S., Goldie S., et al. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ 85 (2007) 719-726
3. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
4. Bosch F.X., Lorincz A., Muñoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
5. Schiffman M., Castle P.E., Jeronimo J., et al. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
6. Brown D.R., Shew M.L., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 (2005) 182-192
7. Moscicki A.B. HPV infections in adolescents. Dis Markers 23 (2007) 229-234
8. Keam S.J., and Harper D.M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed). [ Cervarix™]. Drugs 68 (2008) 359-372
9. Stanley M. Prophylactic HPV vaccines: Prospects for eliminating ano-genital cancer. Br J Cancer 96 (2007) 1320-1323
10. Barr E., and Sings H.L. Prophylactic HPV vaccines: New interventions for cancer control. Vaccine 26 (2008) 6244-6257
11. Koulova A., Tsui J., Irwin K., et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26 (2008) 6529-6541
12. Agosti J.M., and Goldie S.J. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 356 (2007) 1908-1910
13. Frampton J.E., and Keating G.M. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix™): A review of its use as a single-dose booster immunization. BioDrugs 20 (2006) 371-389
14. Vergara R., Tregnaghi M., Ussher J., et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164 (2005) 377-382
15. Descamps D., Hardt K., Spiessens B., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5 (2009) 332-340
16. Harper D.M., Franco E.L., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364 (2004) 1757-1765
17. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
18. Harper D, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with Cervarix™ (GSK's HPV 16/18 AS04 candidate vaccine) [abstract]. Paper Presented at: Society of Gynecologic Oncologists 39th Annual Meeting on Women's Cancer; March 9-12, 2008; Tampa, FL.
19. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
20. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
21. Dagan R., Igbaria K., Piglansky L., et al. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J 16 (1997) 1113-1121
22. Gylca R., Gylca V., Benes O., et al. A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10, and 14 weeks following HBV at birth. Vaccine 19 (2000) 825-833
23. Dessy F.J., Giannini S.L., Bougelet C.A., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 4 (2008) 425-434
24. Theeten H., Rumke H., Hoppener F.J., et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 23 (2007) 2729-2739
25. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006) 1-34
26. Wheeler C.M., Bautistac O.M., Tomassinic J.E., et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26 (2008) 686-696
27. Pedersen C., Petaja T., Strauss G., et al. Immunization of adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571